Clinical Study On Treatment Of Type 2diabetes Mellitus With Sodium-glucose Transporter Protein 2 Inhibitors Dapagliflozin

Objective: To study the changes in the outcome of treatment(types of hemoglobin HbA1 c,fasting plasma glucose FPG,body weight)in patients with type 2 diabetes treated with dapagliflozin.At the same time,the safety of dapagliflozin in treating type 2 diabetes was discussed.Methods: Thirty patients with type 2 diabetes who were admitted to the Department of Endocrinology and Metabolism of the Second Hospital of Lanzhou University from May 2017 to February 2018 were selected as the study subjects,including 19 males and 11 females.57.23±10.33 years old,HbA1 c 8.36±1.19%.Dalgliflozin was given 10 mg for 12 weeks of drug treatment.Three of them withdrew because of poor compliance.A total of 27 cases were completed and all met the WHO(1999)diagnostic criteria for diabetes.All subjects were on the basis of the original hypoglycemic agents hypoglycemic,plus daily dapagliflozin 10mg(before meals can be),and all subjects with exercise therapy and diet control,treatment duration after 12 weeks,subjects were evaluated for the average change in Hb A1 c,FPG,and BW compared to baseline before treatment.Result:1.Dapagliflozin 10 mg for 12 weeks of continuous treatment can effectively control the status of HbA1 c in patients with type 2 diabetes.After treatment,the average HbA1 c of the subjects was 7.70±1.02%.Compared with before treatment,the HbA1 c decreased by 0.66±0.31%,P<0.05,which was significantly different.At the same time,the percentage of the patients with glycosylated hemoglobin(Hb A1c)≤ 7% after treatment was 29.63% of all subjects.2.Dalgliflozin 10 mg for 12 weeks of continuous treatment can effectively control fasting plasma glucose(FPG)in patients with type 2 diabetes.After treatment,the fasting plasma glucose(FPG)of the subjects was 8.42±1.86 mmol/L,which was an average decrease of 1.77±1.15mmol/L compared with pre-treatment fasting plasma glucose(FPG),P<0.05,with statistical difference.3.Dapagliflozin 10 mg for 12 weeks of continuous treatment can effectively control the body weight(BW)of patients with type 2 diabetes.After treatment,the average body weight of the subjects was 74.36±11.59 kg,and the average weight of the subjects before treatment was decreased by 1.67±0.68 kg,P<0.05.There was a statistically significant difference.4.No serious adverse reactions such as severe hypoglycemia,nocturnal hypoglycemia,urinary tumor,and drug allergy were observed during the entire study.The adverse reactions that occurred accounted for 3.7% of all subjects and could be relieved after symptomatic treatment.Conclusions: By analyzing the results of applying dapagliflozin 10 mg for 12 weeks in T2 DM patients,HbA1 c,fasting plasma glucose,and body weight were improved after taking dapagliflozin,and there were no serious side effects such as hypoglycemia and urinary tract infection during the study..These findings suggest that the sodium-glucose cotransporter 2inhibitor dapagliflozin is effective and well-tolerated for the treatment and management of type 2diabetes.